Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Up 58.4% in November

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 173,900 shares, an increase of 58.4% from the October 31st total of 109,800 shares. Currently, 3.6% of the company’s shares are sold short. Based on an average daily volume of 76,900 shares, the days-to-cover ratio is presently 2.3 days.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th.

Brainstorm Cell Therapeutics Price Performance

Shares of Brainstorm Cell Therapeutics stock opened at $1.74 on Friday. Brainstorm Cell Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $11.89. The business has a 50-day moving average price of $2.03 and a 200 day moving average price of $4.37.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is owned by hedge funds and other institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.